photo-1456374407032-6e4baf58fb62.jpeg
stem-cell-163711.jpg
types-738846.jpg
photo-1456374407032-6e4baf58fb62.jpeg

ImevaX


Pioneering Next Generation Vaccines

SCROLL DOWN

ImevaX


Pioneering Next Generation Vaccines

At ImevaX, we develop new vaccines against chronic and nosocomial infections. Our lead product is IMX101, a novel approach to fighting Helicobacter pylori. With this vaccine we will be first in class in the market. 

Over half of the world’s population is infected with the bacterium Helicobacter pylori. It can lead to stomach ulcers and is the primary cause of stomach cancer.

Recently, the clinical development plan for our lead product was approved. Now ImevaX is a clinical stage company evaluating IMX101 in a phase I trial.

 
stem-cell-163711.jpg

Science


Developing Next Generation Vaccines 

Science


Developing Next Generation Vaccines 

 

Over millions of years, bacteria developed strategies to circumvent our immune system. To fight these bacterial infections, we identify the immune evasion mechanisms and use them against the bacteria.

Our novel mode-of-action operates twofold: it disarms the immune evasion mechanisms of the bacterium. At the same time, the host’s immune system is enabled to tackle the infection.

IMX101 against Helicobacter pylori, currently tested in a clinical phase I trial, is an outstanding example for the next generation of vaccines.